April 2026 in “Journal of Dermatological Science” This study highlights that hair-bearing organoids derived from embryonic stem cells can effectively model androgenic alopecia conditions and test the efficacy of anti-hair loss treatments.
In this study, baseline neutrophil-to-lymphocyte ratio (NLR) was associated with predicting early trichoscopic response in patients undergoing PRP-based treatment for non-scarring alopecia.
This study found that in the Jordanian population, elevated cortisol levels were significantly associated with progressive keratoconus, whereas lower cortisol levels were linked to stable disease, suggesting cortisol may be a potential biomarker for monitoring keratoconus progression.
March 2026 in “Expert Opinion on Pharmacotherapy” This review highlights that JAK inhibitors have transformed severe alopecia areata treatment by disrupting disease signaling, emphasizing the need for strategies to address non-responders and manage treatment discontinuation.
February 2026 in “Expert Review of Endocrinology & Metabolism” This review discusses the dermatologic manifestations and management of polycystic ovary syndrome, underscoring the need for mechanism-based, personalized treatments and integrated mental health support, but reports no new clinical results.
January 2026 in “Non-coding RNA Research” This study found that low-passage exosomes from dermal papilla cells enhance hair follicle stem cell proliferation and that miR-218-5p may serve as a potential biomarker and therapeutic target for hair growth.
January 2026 in “Frontiers in Molecular Biosciences” This study identified a four-gene loop as a non-invasive biomarker that selectively activates in alopecia areata, providing a precise target for JAK inhibitor treatments.
January 2026 in “International Journal of Biological Macromolecules” This study used a new multimolecular spectral method to uncover structural differences in hair keratin from individuals with androgenetic alopecia compared to healthy individuals, identifying potential biomarkers and providing insights for developing new treatments.
January 2026 in “Burns & Trauma” This review synthesizes evidence on how RNA modifications affect wound healing, particularly in skin, bone, and corneal injuries, emphasizing potential therapeutic strategies for burns and trauma in relation to these cellular processes.
December 2025 in “Journal of Cell Communication and Signaling” This review discusses the role of vitamin D receptor signaling in hair follicle biology for alopecia treatment and underscores the need for continued research, without presenting new clinical results.
December 2025 in “Asian Journal of Advanced Research and Reports” This study found that measuring stress biomarkers in hair could be an effective and simpler method for assessing chronic stress in rats, potentially offering a novel alternative to serum tests with biomarkers including sodium, calcium, and cortisol.
December 2025 in “Frontiers in Endocrinology” This study found that elevated CgA levels in PCOS are associated with obesity, insulin resistance, and low-grade inflammation, suggesting CgA may be a novel biomarker for metabolic risk stratification in PCOS.
December 2025 in “Clinical Cosmetic and Investigational Dermatology” This study highlights the potential of ZDHHC17 methylation as a biomarker or therapeutic target in addressing skin aging, offering new insights into its molecular mechanisms.
November 2025 in “BMC Endocrine Disorders” This study found that in PCOS patients, a lower TT/DHT ratio is associated with regular menstruation, while higher ratios are linked to insulin resistance, suggesting its potential as a biomarker for metabolic severity in these patients.
November 2025 in “British Journal of Dermatology” This guideline by the British Association of Dermatologists reviews managing alopecia areata and provides 56 recommendations but reports no new clinical results.
November 2025 in “Scholarly Commons (Embry–Riddle Aeronautical University)” This review discusses how urban air pollutants may influence the regulation of JAK3 signaling in alopecia areata and reports no new experimental results; the authors integrate existing data to map potential pathways and biomarkers.
November 2025 in “Clinical and Translational Medicine” This study found that cell-free RNA, particularly DNAJB9, shows potential as a biomarker for diagnosing and prognosing female androgenetic alopecia using a machine learning model.
October 2025 in “European Journal of Translational and Clinical Medicine” This study found that women with polycystic ovary syndrome had significantly higher serum dihydrotestosterone levels than healthy controls, supporting its use as a reliable biomarker for early detection of the condition.
October 2025 in “International Journal of Molecular Sciences” This study identified changes in immune activation, ferroptosis, and structural genes in alopecia areata subtypes, suggesting molecular markers that might help understand disease variability and guide future treatments.
September 2025 in “Cancer Innovation” This study argues for "clinical trial re-innovation," highlighting new designs like basket, umbrella, and platform trials that incorporate biomarker technologies to meet the dynamic needs of precision medicine, potentially enabling more effective, patient-specific treatments and overcoming limitations of traditional disease-centered trials.
July 2025 in “Nano Research” This review highlights the application of microneedle technology as a promising advancement in psoriasis management, focusing on its roles in enhanced transdermal drug delivery and minimally invasive biomarker monitoring, while also discussing current challenges and future research directions.
July 2025 in “Frontiers in Medicine” In this case study, an 8-year-old boy with alopecia totalis experienced significant hair regrowth after baricitinib treatment, suggesting KRT74 variants may influence immune dysregulation in this condition.
July 2025 in “Chinese Journal of Dermatology” This study reported differences in serum IgG N-glycans between male patients with different types of androgenetic alopecia, suggesting that GP10 and GP22 may serve as biomarkers for assessing hair loss severity in male FPHL.
July 2025 in “The Egyptian Journal of Hospital Medicine” This study found that serum GPER-1 levels may serve as a biomarker for differentiating androgenetic alopecia from telogen effluvium and healthy controls, although its ability to distinguish between AGA and TE is limited.
June 2025 in “Medical Science Journal for Advance Research” This study found that patients with Alopecia Areata had significantly higher levels of the chemokines MIG and IP-10 compared to healthy controls, suggesting these molecules may serve as potential biomarkers for diagnosing and monitoring the condition.
May 2025 in “OSF Preprints (OSF Preprints)” Machine learning can help identify stress indicators in mothers and infants.
May 2025 in “Preprints.org” This study identified a unique circulating microRNA signature associated with severe alopecia areata, distinguishing it from other inflammatory skin conditions and suggesting these miRNAs as non-invasive biomarkers for diagnosis and potential therapeutic targets.
March 2025 in “Archives of Dermatological Research” miR-155-5p can help diagnose and track alopecia areata severity.
March 2025 in “GSC Biological and Pharmaceutical Sciences” In this review, the authors examined the potential benefits of using wood tar in dermatology and cosmetics in Sub-Saharan Africa, based on its historical application in skin care and its worldwide usage.
January 2025 in “Acta Dermatovenerologica Alpina Pannonica et Adriatica” In this study, oral minoxidil treatment significantly increased serum VEGF levels and improved hair growth measures compared to a control group, suggesting its potential as an effective approach for promoting hair regrowth in androgenetic alopecia.